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A B S T R A C T
Background
In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti-factor VIII antibodies,
known as ’inhibitors’. Drugs insensitive to such antibodies, either recombinant or plasma-derived, are called factor VIII ’by-passing’
agents and used for treatment of bleeding in people with inhibitors.
Objectives
To determine the clinical effectiveness of recombinant factor VIIa concentrate compared to plasma-derived concentrates for treating
acute bleeding episodes in people with haemophilia and inhibitors.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Coagulopathies Trials Register which comprises references
identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference
proceedings.
Date of the most recent search of the Group’s Coagulopathies Trials Register: 23 September 2015.
Selection criteria
Randomised and quasi-randomised controlled clinical trials comparing recombinant factor VIIa concentrate to human plasma-derived
concentrates (high-dose human or recombinant factor VIII or factor IX concentrate; non-activated prothrombin complex concentrates;
activated prothrombin complex concentrates) in people with haemophilia. Comparisons with animal-derived products were excluded.
Data collection and analysis
Two authors independently assessed the trials (eligibility and risk of bias) and extracted data.No combinedmeta-analyses were performed
due to the unavailability of outcomes and comparisons common to the included trials.
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Main results
A total of 15 trials were identified, two of which (with data for a total of 69 participants) were eligible for analysis. Both trials showed
methodological flaws and did not show superiority of one treatment over the other. Both the treatments showed that recombinant factor
VIIa and activated prothrombin complex concentrate appeared to have a similar haemostatic effect in both trials, without increasing
thromboembolic risk.
Authors’ conclusions
Based on the separate analysis of the two available randomised trials, recombinant factor VIIa and activated prothrombin complex
concentrate were found to be similar in efficacy and safety. However, there is a need for further, well-designed, adequately-powered,
randomised controlled trials to assess the relative benefits and risks of using recombinant factor VIIa compared to human plasma-
derived concentrates in people with haemophilia with inhibitors. It is advisable that researchers in the field define commonly agreed
objective outcome measures in order to enable the pooling of their results, thus increasing the power of comparisons. To date, data
could not be combined in a formal meta-analysis. For the same reason reporting concordant and discordant pairs in cross-over trials is
recommended.
P L A I N L A N G U A G E S U M M A R Y
Recombinant (non-human) factor VIIa clotting factor concentrates versus plasma concentrates for acute bleeds in people with
haemophilia and inhibitors
Review question
Wewanted to find evidence on the effectiveness of recombinant factor VIIa (containing no human proteins) as compared to concentrates
derived from plasma for treating acute bleeding episodes in people with haemophilia with inhibitors.
Background
Haemophilia is an inherited bleeding disorder caused by a lack of a clotting factor and is characterised by bleeding into the joints. It
is treated by injecting a drug containing the missing clotting factor into veins. In some individuals with haemophilia, this factor is
seen by the body as a foreign protein when it is injected and the body produces an antibody (inhibitor) that destroys the factor. In this
way these people become resistant to treatment. Once someone with haemophilia develops an inhibitor, they are treated to remove the
antibody (immunotolerance induction) and for acute bleeding episodes. Treatment for bleeding episodes is with one of two available
bypassing agents, recombinant activated factor VIIa (Novoseven®) or human activated prothrombin complex concentrate (FEIBA®).
It is not known if one of these products is better than the other. We searched for trials comparing the effectiveness (time until bleeding
stops, effect on joint motion, need for re-treatment) and safety of Novoseven® and FEIBA® in people with haemophilia with inhibitors
during episodes of acute bleeding.
Search date
The evidence is current to: 23 September 2015.
Study characteristics
The review included two trials with 69 people (aged one to 55 years) with severe haemophilia with inhibitors. Both trials compared
recombinant factor VIIa with activated prothrombin complex concentrate and people were selected for one treatment or the other
randomly.
Key results
We found two clinical trials comparing Novoseven® and FEIBA®. The trials did not show a difference in how well the two products
worked and both were tolerated equally well with no clotting complications. We conclude that both recombinant factor VIIa and
plasma-derived concentrates can be used to treat bleeds in people with haemophilia and inhibitors.
Quality of the evidence
There were some major problems with regards to the way both trials were designed, in relation to knowing which treatment group each
person was in (both before the trial was started and during) and also how missing results were handled.
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B A C K G R O U N D
Description of the condition
Haemophilia is an inherited disorder where affected individuals
suffer from excessive bleeding. It is inherited as an X-linked disor-
der, but in around a third of all cases no family history is present.
People with haemophilia develop spontaneous bleeding into joints
and suffer excessive bleeding after injury or surgery which can be
hazardous unless appropriately managed in expert centres. Two
main types are recognised due to either a deficiency of factor VIII
(FVIII) (haemophilia A) or of factor IX (FIX) (haemophilia B).
The prevalence is similar worldwide and for haemophilia A is 1
in 10,000 and for haemophilia B is 1 in 60,000 births (Mannucci
2001).
The severity of the phenotype depends on the baseline concentra-
tion of the clotting factor. The severity of haemophilia has been de-
fined by the International Society for Thrombosis and Haemosta-
sis as:
• severe, where the factor is less than 0.01 units per millilitre
(u/ml);
• moderate, where the factor ranges from 0.01 u/ml to less
than 0.05 u/ml; and
• mild, where the factor is greater than 0.05 u/ml (White
2001).
Spontaneous bleeding into joints is seen primarily in people with
severe haemophilia.
Description of the intervention
The mainstay of treatment in bleeding disorders due to factor
deficiency is the correction of the defect by the intravenous in-
fusion of the appropriate clotting factor. For haemophilia, ini-
tially in the 1960s this consisted of the infusion of fresh frozen
plasma (haemophilia A and haemophilia B) and cryoprecipitate
(haemophiliaA) andwas followed in the 1970s by the introduction
of FVIII (haemophilia A) or FIX (haemophilia B) concentrates.
Over the last 30 years the purity of concentrates has increased; and
since 1985 viral inactivation procedures were introduced to elimi-
nated blood product-transmitted infections such as HIV and hep-
atitis C (Rizza 2001). At the beginning of the 1990s recombinant
factor concentrates (that do not contain human proteins) were
developed and these have entered clinical practice (UKHCDO
2003).
In some people with haemophilia the administered factor is recog-
nised as a foreign protein and anti-FVIII or anti-FIX antibodies are
produced. These antibodies are referred to as inhibitors when they
inhibit the activity of the administrated factor. The reported preva-
lence of inhibitors in haemophilia A varies enormously from 3.6%
(Yee 1999) to 32% (Kreuz 2002). The incident rate of inhibitors is
much lower in haemophilia B than in haemophilia A, but inhibitor
treatment in haemophilia B is hampered by complications due
to immuno-complex mediated renal damage (Ewenstein 1997).
The risk of developing an inhibitor has been found to be asso-
ciated with: the causative genetic defect (Dimichele 2002), with
gene deletions having the highest risk of developing an inhibitor
(Goodeve 2003); ethnicity; family history of haemophilia with or
without inhibitors; the length and intensity of exposure to factor
concentrates; the age at first exposure; and the occurrence of a
trigger event (i.e. bleeding, surgery or infections). Other reasons
for the varying prevalence of inhibitors observed in different pub-
lished reports may be the laboratory method for measuring the
inhibitor as well as the frequency of inhibitor testing. The lower
prevalence of gene deletions in haemophilia B partly explains the
lower rate of inhibitor development (DiMichele 2007).
There are two key elements in the treatment of people with
haemophilia with inhibitors. The first, which is addressed by this
review, is the treatment of the individual to arrest the acute bleed-
ing. The second element is treatment to eliminate the inhibitor
(immune tolerance induction), which is the subject of another
Cochrane review (Athale 2014).
How the intervention might work
The acute treatment of someone with haemophilia and an in-
hibitor depends on the level of the antibody or inhibitor that is
measured in vitro and is quantified in Bethesda units. A Bethesda
unit is a measure of inhibitor activity and is the amount of in-
hibitor that will inactivate 50% or 0.5 unit of a coagulation fac-
tor in an activated partial thromboplastin time (aPTT)-based co-
agulation factor assay following a two-hour incubation period in
an imidazole buffer diluted sample. Although some people with
haemophilia with low levels of inhibitor can be treated with stan-
dard concentrates, in practice most have inhibitors that destroy
the infused FVIII or FIX and other products have been developed
to treat these individuals. These are based on human plasma such
as activated prothrombin complex concentrates (aPCC) (brands
available are FEIBA® and Autoplex®) or non-activated prothrom-
bin complex concentrates (PCC) or animal plasma such as Hyate-
C® (FVIII prepared from porcine plasma, can be used in peo-
ple with haemophilia with no antibodies to porcine FVIII) (Hay
2000). A more recent alternative approach has been the use of re-
combinant FVIIa concentrate (rFVIIa) (NovoSeven®), which was
introduced early in the 1990s and shown to be highly effective but
also associated with a relatively high cost (Hedner 2000). Mainly
aPCC exerts its effect by providing activated factor IX and X,
which are able to produce a significant amount of thrombin with-
out any requirement for FVIII (Thomas 1977); noticeably, aPCC
is not expected to be active in people with factor IX deficiency. At
a pharmacological concentration, rFVII is able to directly activate
thrombin when bound to tissue factor or to activate factor Xa on
the surface of activated platelets (Hedner 2000). The difference in
the mechanism of action of the two compounds makes it reason-
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able to switch the non-responding individual from one treatment
to the other, and to assess the efficacy and safety of the combina-
tion of the two drugs.
Why it is important to do this review
This review investigates which is the most effective treatment of
acute bleeding in people with haemophilia with inhibitors.
O B J E C T I V E S
To determine the clinical effectiveness of rFVIIa in comparison to
PCC or aPCC for treating acute bleeding episodes in people with
haemophilia with inhibitors.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised (RCTs) and quasi-randomised controlled clinical tri-
als.
Types of participants
Children and adults with haemophilia, of all degrees of severity
diagnosed by decreased blood levels of functional procoagulant
FVIII or FIX and with FVIII or FIX inhibitors of any titre.
Types of interventions
Recombinant FVIIa concentrate (rFVIIa) compared to human
plasma-derived concentrates (high-dose human or recombinant
FVIII or FIX concentrate; PCCs; aPCC). Comparisons with ani-
mal-derived products were excluded.
Types of outcome measures
Primary outcomes
1. Early cessation of bleeding measured by
i) changes on any subjective or objective pain and
mobility scale or
ii) by the volume of haematoma assessed radiologically at
any point in the first 48 hours
Secondary outcomes
1. Number of participants requiring additional or alternative
treatment
2. Number of participants with adverse effects (thromboses;
allergic reactions)
3. Correction of abnormal haemostatic laboratory test results
Search methods for identification of studies
No restrictions based on dates, language or publication status were
imposed.
Electronic searches
Relevant trials were searched for on the Group’s Coagulopathies
Trials Register using the terms: (haemophilia A AND factor VIIa)
OR (haemophilia B AND factor VIIa) OR (haemophilia general
AND (recombinant factor VIIa OR factor VIIa))
The coagulopathies register is compiled from electronic searches of
the Cochrane Central Register of Controlled Trials (CENTRAL)
(updated each new issue ofThe Cochrane Library), weekly searches
of MEDLINE and the prospective handsearching of one journal
- Haemophilia. Unpublished work is identified by searching the
abstract books of four major conferences: the European Haema-
tology Association conference; the American Society of Hema-
tology conference; the British Society for Haematology Annual
Scientific Meeting; and the Congress of the World Federation of
Haemophilia. For full details of all searching activities for the regis-
ter, please see the relevant section of the Cochrane Cystic Fibrosis
and Genetic Disorders Group Module.
Date of the most recent search of the Cystic Fibrosis and Genetic
Disorders Group’s Coagulopathies Trials Register: 23 September
2015.
Data collection and analysis
Selection of studies
In the 2010 update, two trials were found to be eligible for in-
clusion (Astermark 2007; Young 2008). Additional data were ob-
tained from trial authors for the 2015 update and included in the
review (Astermark 2007; Young 2008).
For the references found when updating the review after October
2007, two authors (AI,DM) independently selected the trials to be
included in the review.When disagreement arose on the suitability
of a trial for inclusion in the review or on its quality, we attempted
to reach a consensus by discussion.
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Data extraction and management
Two authors (AI, DM) independently extracted data using stan-
dard data acquisition forms.When disagreement arose on the suit-
ability of a trial for inclusion in the review or on its quality, we
reached a consensus by discussion.
Assessment of risk of bias in included studies
Two authors (AI, DM) assessed the risk of bias of each trial. In
particular, they examined details of the randomisation method,
whether the trial was blinded, whether intention-to-treat analyses
were possible from the available data and if the number of partic-
ipants lost to follow up or subsequently excluded from the study
was recorded.When disagreement arose on the suitability of a trial
for inclusion in the review or on its quality, we reached a consensus
by discussion.
Randomisation method
Weassessed the risk of bias from the randomisation sequence as low
if this was generated using, e.g. a computer or a random numbers
table; we assessed the risk of bias as unclear if themethods were not
described; and we assessed the risk of bias as high if a non-random
approach was used, e.g. date of birth, clinical record number.
Concealment of allocation
We assessed the risk of bias from concealment of allocation as low
if neither the participants or trial investigators could foresee the
allocation of the participants (e.g. using sealed opaque envelopes);
we assessed the risk of bias as unclear ifmethodswere not described;
and we assessed the risk of bias as high if alternation or an open
allocation schedule was used.
Blinding
We assessed the risk of bias from blinding as low if participants,
investigators and outcome assessors were blinded (or if any of these
were not blinded but outcome assessment was blinded and this
was judged not to influence the outcome); we judged the risk of
bias as unclear if this issue was not discussed; and we judged the
risk of bias to be high if none of the parties involved in the trial
were blinded.
Incomplete outcome data
We judged the risk of bias to be low if any withdrawals were
described in full and were equal across groups; we judged the risk
of bias to be unclear if insufficient information was given; and we
judged the risk of bias to be high if the missing data were likely
to be directly related to the outcome or if they were uneven across
groups.
Measures of treatment effect
For binary outcome measures, we sought data on the number of
participants with each outcome event, by allocated treated group,
irrespective of compliance and whether or not the participant was
later thought to be ineligible or otherwise excluded from treat-
ment or follow-up. We aimed to calculate a pooled estimate of the
treatment effect for each outcome across studies using the odds
ratio (OR) (the odds of an outcome among treatment allocated
participants to the corresponding odds among controls).
For continuous outcomes, we recorded either mean change from
baseline for each group or mean post-treatment or intervention
values and standard deviation (SD) for each group. Then, where
appropriate, we planned to calculate a pooled estimate of treatment
effect by calculating the mean difference (MD). If different scales
had been used for the same outcome we would have considered
using the standardised mean difference (SMD).
Unit of analysis issues
As we expected to find cross-over trials, we decided to analyse
cross-over trials with themarginal probabilities of success method,
as described by Elbourne, (Becker 1993; Elbourne 2002) rather
than examining them as a parallel trial. Analysing cross-over trials
in this way has been reported to avoid the problem of losing the
advantage arising from cross-over trials (Elbourne 2002).
Dealing with missing data
We sought the necessary data from the original investigators if
reports were incomplete. This refers particularly to the data needed
to apply the marginal probabilities method to cross-over trials
(Becker 1993; Elbourne 2002).
Assessment of heterogeneity
We planned to test heterogeneity between trial results using a
standard Chi2 test and the I2 statistic using the following cut-off
values (Higgins 2003):
• not important heterogeneity: 0% to 40%;
• moderate heterogeneity: 30% to 60%;
• substantial heterogeneity: 50% to 90%;
• considerable heterogeneity: 75% to 100%.
Assessment of reporting biases
We planned to assess publication bias by visual inspection of the
funnel plot, and to investigate outcome reporting bias by compar-
ing trial protocols and results from final papers, or (if protocols
are not available) the methods and results sections of final papers.
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Data synthesis
For themeta-analysis we planned to use a fixed-effect model unless
we found moderate or significant heterogeneity, in which case we
planned to use a random-effects model.
Subgroup analysis and investigation of heterogeneity
If we had identified moderate or significant heterogeneity, we
planned to investigate this by subgroup analysis based on the level
of the inhibitor (Hay 2000):
1. levels of 5 Bethesda units per millilitre (BU/ml) or less;
2. levels in excess of 5 BU/ml.
Sensitivity analysis
We planned to perform a sensitivity analysis based on the gener-
ation of the allocation sequence within the trials, including and
excluding quasi-randomised trials.
R E S U L T S
Description of studies
Results of the search
A total of 15 studies were identified by the searches (Astermark
2007; Young 2008; Chuansumrit 2000; de Paula 2012;
Kavakli 2006; Ljung 2013; Lusher 1998; Mahlangu 2012;
NCT00108758; NCT01561391; Pruthi 2007; Santagostino
2006; Seremetis 1994; Shapiro 1998; Villar 2004) and two of these
were eligible for inclusion in this review (Astermark 2007; Young
2008). The reasons for excluding the 13 studies are summarized
below (Characteristics of excluded studies).
Included studies
Trial design
Both of the included trials were multicentre cross-over RCTs. One
trial had two arms (Astermark 2007) and the second trial had three
arms (Young 2008). For the comparison we are evaluating (rFVIIa
versus aPCC) the trials were unblinded.
Participants
Participants in both trials included adults and children with severe
haemophilia with inhibitors (Astermark 2007; Young 2008). The
Astermark trial only included participants with haemophilia A;
the Young trial included participants with both haemophilia A
and B and did not separately specify the numbers of each.
The Astermak trial enrolled 66 participants; however, 14 with-
drew prior to treatment or were treated only once. Diaries for a
further four participants were not completed (Astermark 2007).
The Young trial randomised 42 participants, with 21 completing
all three treatment arms.
Interventions
Both the included trials compared rFVIIa with aPCC.
In the Young trial, rFVIIa 90 mcg/kg was given as an intravenous
(IV) bolus administered at zero, three and six hours; rFVIIa 270
mcg/kg as single IV bolus (followed by two placebo infusions);
and aPCC 75 IU/kg as a single IV bolus (Young 2008). Thus,
participants were unblinded to the comparison between aPCC
and rFVIIa, but were blinded to the dose of rFVIIa (90 mcg/kg
x 3 doses versus 270 mcg/kg as a single bolus with two placebo
solutions).
In the Astermark trial aPCC 75 to 100 IU/kg (target 85 IU/kg)
was given as a single IV bolus; rFVIIa 90 to 120 mcg/kg (target
105 mcg/kg) was given as an IV bolus repeated after two hours
(Astermark2007). Both treatmentswere administered amean time
of two hours after bleeding onset.
Outcomes measured
In both the trials, due to the peculiarity of the clinical condition
under evaluation, the outcomes were subjective in nature (partic-
ipant judgement about the efficacy of the treatment, expressed as
global evaluation, pain cessation, motility improvement, need for
additional treatment). None of the outcomes measures used were
common to both trials, and only one of them made assessments
about the safety of the treatment (Young 2008). The primary and
secondary outcomes of the Young trial were the secondary and
primary outcomes of this review, respectively (Young 2008).
Excluded studies
Among the excluded trials, two were not RCTs or quasi-RCTs
(Chuansumrit 2000; Seremetis 1994), five were dose-finding tri-
als, where the comparators were not alternative therapies (Lusher
1998; Shapiro 1998;Villar 2004;Mahlangu 2012; de Paula 2012);
the remaining six were randomised comparisons of different regi-
mens of rFVIIa given to treat bleeding (Kavakli 2006; Santagostino
2006; Ljung 2013; NCT00108758) or as surgical prophylaxis
(Pruthi 2007; NCT01561391).
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Risk of bias in included studies
Allocation
Generation of randomisation sequence
In one trial randomisation in association with the first bleeding
event was performed in a block of participants equally divided
into two (Astermark 2007). Themethod of randomisation for that
first event is not given in the paper. In the second trial, six treat-
ment sequences were generated by the permutation of the three
dosing regimens (Young 2008). The sequences were randomly as-
signed to the participants. There is no further information about
the method of randomisation in the paper. The risk of bias has to
be considered unclear in both trials due to lack of details about
randomisation sequence generation; furthermore, blocking by two
allows the investigator to guess the treatment assigned to the sub-
sequent participant (Astermark 2007).
Concealment of allocation
Both trials were open label for the comparison of rFVIIa versus
aPCC, which would mean there was sub-optimal allocation con-
cealment. However, in the Young trial the comparison between
the two different rFVIIa regimens did not provide details about
randomisation code concealment. We therefore judged one trial
to be at a high risk of bias (Astermark 2007) and one to be at an
unclear risk of bias (Young 2008).
Blinding
One trial was not blinded for physicians and participants because
of themajor difference between the two products (physical appear-
ance and required volume for injection); outcome assessment was
also not blinded (Astermark 2007). In the second trial, participants
and clinicians could not be blinded to the comparison between
the two rFVIIa treatments and the aPCC treatment due to differ-
ences in physical appearance and required volume for injection,
but comparison between the two rFVIIa treatments was blinded
(three active boluses versus one active and two placebo boluses)
(Young 2008). Outcome assessment in this trial was blinded.
The risk of bias has to be considered high in both trials.
Incomplete outcome data
A total of 48 participants out of 66 completed the Astermark trial
protocol for all time points (Astermark 2007). There were 14 par-
ticipants who withdrew prior to treatment or were treated only
once. Reasons for withdrawal included: no bleeding episodes in
the study joints or the timing of prophylactic or other infusions
prevented participation (six participants); lack of compliance with
the protocol (three participants); concern about using a unfamiliar
product, or change ofmind about participation (two participants);
the trial was stopped by the Ministry of Health in one country
because the products were not provided free of charge (one partic-
ipant); no reason was given for the withdrawal of two participants;
the diaries of four participants were not adequately completed for
inclusion in the analysis. The trial was reported as to be analysed
on an intention-to-treat basis, but actually appears to be analysed
per protocol, we therefore assessed this trial as having a high risk
of bias (Astermark 2007).
A total of 21 participants out of 42 completed the Young trial pro-
tocol (Young 2008). Fourteen participants were randomised but
not treated; of the remaining 27 participants, six were withdrawn:
three of these for non-compliance; two for study closure; and one
because the participant moved to another centre. The trial was
prematurely interrupted and analysed per protocol and thus as-
sessed as having a high risk of bias (Young 2008).
Selective reporting
We were not able to compare the trial protocols and reports for
either trial, due to unavailability of the protocols (Astermark 2007;
Young 2008). No discrepancy was found between the methods
and results sections of the reports. The outcomes and timing were
those commonly used in the field and pre-specified as outcome
measures for this review. We therefore judge there to be a low risk
of bias from selective reporting.
Other potential sources of bias
Only one of the trials had an objective rather than a subjective
measure as the principal outcome (Young 2008); and a risk of bias
is inherent in the use of any subjective outcomes (participant-re-
ported measures). The use of analgesics was allowed during both
trials, and potentially interferedwith subjective pain assessment by
the participants. One trial evaluated the distribution of analgesics
in the treatment groups (Astermark 2007). The remaining trial
tried to adjust for the concomitant use of analgesic drugs (Young
2008). A significantly different number of knee (higher in rFVIIa-
treated participants) and elbow (higher in aPCC-treated partici-
pants) bleeding events were recorded in one trial and the analy-
sis technique used to balance for the uneven distribution of knee
bleeds is unfair and not sufficiently detailed (Astermark 2007).
The Young trial was interrupted by the sponsor for unspecified
reasons (Young 2008).
Effects of interventions
We are unable to perform any formal meta-analyses because the
two trials did not have any overlapping outcomes amenable for
pooling; therefore, we have simply summarized the results of each
of the trials. The authors of both trials provided the data needed
to perform the marginal probabilities of success method, namely
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the number of participants in each of the following groups, for all
the relevant outcomes at each reported time-point: success in both
treatment phases; failure in both treatment phases; success with
rFVIIa; and failure with aPCC; failure with rFVIIa; and success
with aPCC. As previously described by Elbourne, analysing cross-
over trials in this way has been reported to avoid the problem of
losing the advantage arising from cross-over trials (Becker 1993;
Elbourne 2002). This is our primary analysis and results are re-
ported in the forest plots (Data and analyses). We have also re-
ported the outcome effect measures provided in the original trials
in additional tables (Table 1; Table 2; Table 3; Table 4; Table 5).
Primary outcomes
1. Early cessation of bleeding
a. changes on any subjective or objective pain and mobility
scale
The primary outcome of the Astermark trial was evaluation of
haemostatic effect at six hours following treatment (Astermark
2007). An effective response was defined by creating a dichotomy
of the effective and partially effective response versus poorly effec-
tive and not effective. Full details of the results analyzed with the
marginal probabilities method (Becker 1993) for this outcome are
presented (Analysis 1.1). A secondary outcome of the Astermark
trial, not included in our protocol, is also reported in the addi-
tional tables (Table 2).
The main outcome of the Young trial was an algorithm taking
into account pain and mobility scores, and it did not find any
significant difference between the treatment groups (Young 2008)
(Table 3; Table 4). This algorithm has not, as yet, been formally
validated. The marginal probability score (Becker 1993) was re-
calculated separately for mobility and pain for the assessments at
one, three, six and nine hours (Analysis 2.1; Analysis 2.2; Analysis
3.1; Analysis 3.2; Analysis 4.1; Analysis 4.2). The number of par-
ticipants requiring analgesic drugs was not significantly different
among the treatment groups (Analysis 2.3; Analysis 3.3; Analysis
4.3).
b. changes in the volume of haematoma assessed
radiologically at any point in the first 48 hours
This outcome has not been assessed by either trial.
Secondary outcomes
1. Number of participants requiring additional or alternative
treatment
In the Astermark trial additional doses were administered in
cases where the protocol treatment regimen was not sufficient
(Astermark 2007). The timing of the additional doses varied. A
small number (two) were administered within the first six hours
after onset of treatment. The remainder during the balance of the
48-hour observation period (Astermark 2007).
In the Young trial, participants with an insufficient treatment re-
sponse within six hours of the first treatment administration were
evaluated in the clinic or by telephone to consider the use of res-
cue medication (Young 2008). Rescue medication was defined as
additional haemostatic treatment within nine hours after the first
administration of trial product. A total of eight bleeding episodes
for aPCC, two for rFVIIa 270 mcg/kg and two for rFVIIa 90 mcg/
kg x 3 doses required additional medication. The difference be-
tween rFVIIa 270 mcg/kg versus aPCC was statistically significant
(P = 0.032). The efficacy difference between the aPCC treatment
group and the rFVIIa 90 mcg/kg x 3 doses did not reach statis-
tical difference (P = 0.069). Full details of the results about this
outcome were provided in the additional tables (Table 5).
2. Number of participants with adverse effects (thromboses;
allergic reactions)
The Astermark trial did not report any trial-related or drug-related
adverse effects (Astermark 2007).
The Young trial did not report any thrombotic, fatal or clinical
laboratory adverse events; however, it did record 32 treatment
emergent adverse events in 14 participants. Of these three were
in the rFVIIa 270 mcg/kg group, five were in the rFVIIa 90 mcg/
kg x 3 doses group and six were in the aPCC group. None were
considered to be related to the trial drug (Young 2008).
3. Correction of abnormal haemostatic laboratory test
results
This outcome has not been assessed in either trial. It has to be
noted that no commonly available test exists to monitor the effect
of by-passing agents (both aPCC and rFVIIa).
D I S C U S S I O N
Since the previous version of this review (Iorio 2010), 18 new
potentially relevant references were found. Five trials were added
to the excluded studies list and we did not find any further eli-
gible trials. Therefore, results presented in this update continue
to refer to the two trials already included in the 2010 version of
this review (Iorio 2010). However, we were successful in obtaining
additional data enabling us to perform the marginal probabilities
analysis, although data were still not combined in a formal meta-
analysis (Astermark 2007; Young 2008). The new data allowed us
to report odds ratios (OR) and to take into account information
provided by both treatment periods in the cross-over trials. There
is no change in statistical non-significance of the results. Overall,
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both the included trials showed methodological flaws. Both the
treatments were shown to be effective and safe and can be used
to treat bleeding in people with haemophilia with inhibitors, but
were not able to prove superiority of one treatment over the other.
It is to be noted that the Astermark trial was designed and anal-
ysed as a equivalence trial (Astermark 2007); the Young trial was
aimed at comparing two different dosages of recombinant factor
VIIa (rFVIIa) and used activated prothrombin complex concen-
trates (aPCC) as a reference, without pre-stating any equivalence
range (Young 2008). The high number of dropouts in both trials
is an important limitation. These data do not show whether the
treatments were equivalent or whether one is superior to the other.
Due to the widespread use in clinical practice of both by-passing
agents, their efficacy was considered as already proven, and no
placebo group was felt to be needed. A significant percentage of
dropouts was recorded in both trials, and the Young trial was pre-
maturely discontinued (Young 2008). We would like to highlight
that we found a relevant difference in treatment efficacy indepen-
dent of the drug used, i.e. aPCC or rFVIIa, among the two trials
(median efficacy of 80% at six hours in the Astermark trial and
40% in the Young trial); this means that both trials showed sim-
ilar effectiveness of treatment. The difference in median efficacy
rates is likely to be related to the subjective nature of the outcome
measures or trial protocols or both. With regards to outcome as-
sessment, it is important to note that no objective method is fully
validated as far as joint bleeding is concerned. Similarly, there is no
general consensus on when assessing the anti-haemorrhagic effect.
The two trials used different scales and assessment times, and in
particular the Young trial used a composite algorithm to give an
overall judgement of the participants response over a wide range
of assessment times (Young 2008). How easily the results of the
trials included in the present review can be reproduced in different
contexts is hard to say.
Based on the available randomised evidence, it is not possible to
consider one treatment more efficacious or safer than the other.
Other systematic reviews may help in the choice of themore effec-
tive concentrates by reviewing non-randomised evidence (Lloyd
Jones 2003); or by using a Bayesian approach to pool randomised
and non-randomised evidence (Treur 2009); or by focusing on
economical aspects (Knight 2009). Another potentially relevant
issue, not considered in this systematic review, is that of viral sa-
fety of the concentrates under evaluation. The general considera-
tions about the safety of recombinant and plasma-derived factor
VIII and IX concentrates might apply also to bypassing agents
(rFVIIa and aPCC). Another aspect to be taken into account is
that aPCC contains traces of factor VIII and could possibly in-
duce an anamnestic response to be potentially avoided in patients
candidate to immunotolerance treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the separate analysis of the two available randomised tri-
als, rFVIIa and aPCC were found to be similar in efficacy and in
causing a low risk of thromboembolic complications. Both drugs
can be administered as single intravenous bolus (270 mcg/kg of
rFVIIa, 75 to 100 IU/kg of aPCC). Other non-randomised evi-
dence can be usefully taken into account in the choice of the more
appropriate treatment in clinical practice. The choice between dif-
ferent regimens of rFVIIa is beyond the scope of this review, and
should be mainly based on general considerations about the use of
recombinant versus plasma-derived concentrates in specific cate-
gories of people (i.e. children).
Implications for research
There is need for further well-designed, adequately-powered ran-
domised controlled trials to assess the relative benefits and risks
of using rFVIIa compared to human plasma-derived concentrates
in people with haemophilia with inhibitors. It is advisable that re-
searchers in the field define commonly agreed objective outcome
measures in order to enable easier pooling of their results thus in-
creasing the power of comparisons. To the same, scope reporting
concordant and discordant pairs in cross-over trials would be rec-
ommended. Both tasks are difficult to pursue, but very relevant
and should be sought in view of the high societal costs of treating
people with haemophilia with inhibitors.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Astermark 2007
Methods Open-label cross-over multicentre RCT.
Participants Individuals with severe haemophilia A with inhibitors not undergoing ITI. A total of 66
individuals were enrolled, but 14 withdrew prior to treatment or were treated only once.
Diaries for a further 4 participants were not adequately completed
Age: mean 27.5 years (range 8 - 55 years).
Mean inhibitor titre 8.6 BU/ml (range 0 - 1800).
96 episodes in 48 participants.
Interventions aPCC (FEIBA®) 75 - 100 IU/kg (target 85 IU/kg) as a single IV bolus.
Activated rFVII (NovoSeven®) 90 - 120mcg/kg (target 105mcg/kg) as IV bolus repeated
after 2 hours
Both treatments were administered a mean of 2 hours after bleeding onset
Outcomes Subjective evaluation of treatment efficacy based on a four level scale (effective, partially
effective, poorly effective, not effective); efficacy was defined as effective or partially
effective by participant rating at 6 hours (primary) and at various times from 2 - 48
hours (secondary)
Subjective evaluation of stop of bleeding (binary outcome).
Additonal treatments and the occurrence of re-bleeding were recorded
Notes Use of analgesics was allowed and its distribution in the treatment group was evaluated
A significantly different number of knee (higher in Novoseven®-treated participants)
and elbow (higher in aPCC-treated participants) bleeding events were recorded. The
analysis technique used to balance for the uneven distribution of knee bleeds is unclear
and not sufficiently detailed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation in association with the first
bleeding event was performed in a block of
participants equally divided into two
Allocation concealment (selection bias) High risk Open-label trial. A randomisation list speci-
fying the order of treatment for enrolled par-
ticipants was provided to each participating
centre
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not possible for physicians and
participants because of difference between
the 2 products (physical appearance and re-
quired volume for injection). Outcome as-
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Astermark 2007 (Continued)
sessment was not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk The trial was analysed on aper protocol basis.
Selective reporting (reporting bias) Low risk Outcome data reported in the methods and
the results sections correspond
Other bias High risk Use of analgesics allowed during the trial.
A significantly different number of knee
(higher in participants treated with Novo-
seven®) and elbow (higher in participants
treated with aPCC) bleeding events were
recorded. The analysis technique used to bal-
ance for the uneven distribution of knee
bleeds is unclear and not sufficiently detailed
Young 2008
Methods Open-label cross-over multicentre 3-tier RCT.
The comparison between rFVIIa and aPCC was open label, while the comparison be-
tween the two different rFVIIa regimens was concealed
Outcome assessor was blinded.
Participants Individuals with severe haemophilia A and B with inhibitor (the number of participants
with A and B was not separately specified). A total of 42 were randomised, with 21
completing all 3 arms of treatment
Age: mean 19.5 years (range 1 - 54 years).
Interventions Activated rrF VII (NovoSeven®) 90mcg/kg as IV bolus administered at 0, 3 and 6 hours.
Activated recombinant factor VII (NovoSeven®) 270mcg/kg as single IV bolus (followed
by 2 placebo infusions)
aPCC (FEIBA®) 75 IU/kg as a single IV bolus.
Outcomes Primary outcomes
Number of participants requiring additional treatment.
Secondary outcomes
Subjective pain and mobility scale rating evaluated as global treatment response (com-
posite end-point) and separately
Rate of adverse events.
Notes The trial states that the analysis was performed on an intention-to-treat basis, but the
data seems to have been analysed on-treatment
Risk of bias
Bias Authors’ judgement Support for judgement
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Young 2008 (Continued)
Random sequence generation (selection
bias)
Unclear risk 6 treatment sequences were generated by
the permutation of the 3 dosing regimens.
The sequences were randomly assigned to
the participants
Allocation concealment (selection bias) Unclear risk The comparison between rFVIIa and
aPCC was open label, while the compar-
ison between the 2 different rFVIIa reg-
imens was described as blinded without
details about randomisation code conceal-
ment
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants and clinicians could not be
blinded to comparison between both
NovoSeven® treatments and the FEIBA
® treatment due to differences in physi-
cal appearance and required volume for in-
jection, but comparison of 2 NovoSeven®
treatments was blinded (3 active versus 1
active and 2 placebo doses). Outcome as-
sessment was blinded for the treatments
Incomplete outcome data (attrition bias)
All outcomes
High risk The trial states that the analysis was per-
formed on an intention-to-treat basis, but
the data seems to have been analysed on-
treatment
Selective reporting (reporting bias) Low risk Outcome data reported in themethods and
results sections correspond
Other bias Unclear risk Use of analgesics allowed during the trial.
Distribution of analgesics use among group
was evaluated
The trial was interrupted by the sponsor for
unspecified reasons
aPCC: activated prothrombin complex concentrates
BU: Bethesda units
ITI: immune tolerance induction
IV: intravenous
RCT: randomised controlled trial
rFVIIa: recombinant factor VIIa
vs: versus
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chuansumrit 2000 Not a randomised or quasi-randomised controlled trial.
Prospective, open-label, uncontrolled, observational study.
de Paula 2012 Dosage-finding trial: comparator is not an alternative therapy
Kavakli 2006 Double-blind cross-over RCT comparing two different regimens of rFVIIa
Ljung 2013 RCT comparing two different regimens of rFVIIa.
Lusher 1998 Dosage-finding trial: comparator is not an alternative therapy.
Double-blind RCT.
Mahlangu 2012 Dosage-finding trial: comparator is not an alternative therapy
NCT00108758 RCT comparing two different regimens of rFVIIa.
NCT01561391 RCT comparing two different regimens of rFVIIa.
Pruthi 2007 Open label randomisedRCTcomparing two different regimens of rFVIIa (90mcg/kg boluses versus continuous
infusion) in people with haemophilia undergoing major surgery
Santagostino 2006 Open label cross-over RCT comparing two different regimens of rFVIIa
Seremetis 1994 Not a randomised or quasi-randomised controlled trial.
Phase II safety and efficacy trial.
Shapiro 1998 Dosage-finding trial: comparator is not an alternative therapy.
Double-blind RCT.
Villar 2004 Dosage-finding trial: comparator is not an alternative therapy
RCT: randomised controlled trial
rFVIIa: recombinant factor VIIa
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D A T A A N D A N A L Y S E S
Comparison 1. aPCC 75 - 100 IU/kg vs rFVIIa 90 - 120 mcg/kg x 2 doses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment efficacy judgement 1 Odds Ratio (Fixed, 95% CI) Totals not selected
1.1 At 2 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 6 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 At 12 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 At 24 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 At 36 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 At 48 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. rFVIIa 270 ug/kg vs rFVIIa 90 ug/kg x 3 doses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mobility evaluation 1 Odds Ratio (Fixed, 95% CI) Totals not selected
1.1 At 1 hour 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 3 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 At 6 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 At 9 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Pain evaluation 1 Odds Ratio (Fixed, 95% CI) Totals not selected
2.1 At 1 hour 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 3 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 At 6 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 At 9 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Need for rescue medication 1 Odds Ratio (Fixed, 95% CI) Totals not selected
Comparison 3. rFVIIa 270 ug/kg vs APCC 75 U/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mobility evaluation 1 Odds Ratio (Fixed, 95% CI) Totals not selected
1.1 At 6 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 9 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Pain evaluation 1 Odds Ratio (Fixed, 95% CI) Totals not selected
2.1 At 1 hour 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 3 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 At 6 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 At 9 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
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3 Need for rescue medication 1 Odds Ratio (Fixed, 95% CI) Totals not selected
Comparison 4. rFVIIa 90 ug/kg x 3 doses vs APCC 75 U/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mobility evaluation 1 Odds Ratio (Fixed, 95% CI) Totals not selected
1.1 At 6 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 9 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Pain evaluation 1 Odds Ratio (Fixed, 95% CI) Totals not selected
2.1 At 1 hour 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 3 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 At 6 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 At 9 hours 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Need for rescue medication 1 Odds Ratio (Fixed, 95% CI) Totals not selected
A D D I T I O N A L T A B L E S
Table 1. aPCC 75-100 IU/kg vs rFVIIa 90 - 120 mcg/kg x 2 doses - Treatment efficacy judgement
Study ID Hours (pts num-
ber)
aPCC n (%) rFVIIa n (%) 90% CI of the difference
(%)
P value
Astermark 2007 2 (48) 36 (75.0) 29 (60.4) -0.73 to 29.9 0.482
6 (47) 38 (80.9) 37 (78.7) -11.42 to 15.67 0.059
12 (45) 38 (80.0) 38 (84.4) -18.08 to 9.19 0.101
24 (42) 40 (95.2) 36 (85.7) -1.29 to 20.33 0.202
36 (41) 41 (100) 37 (90.2) 2.13 to 17.38 0.129
48 (41) 40 (97.6) 35 (85.4) 2.05 to 22.34 0.325
The table reports the number and % of participants who judged the treatment efficacious for any treatment and any time point. The
90% CIs of the difference test the hypothesis of equivalence between the treatments. When considering the difference at 2 hours, it
has to be taken into account that this time point is before the administration of the second rFVIIa bolus.
aPCC: activated prothrombin complex concentrates
CI: confidence interval
rFVIIa: recombinant factor VIIa
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Table 2. aPCC 75 - 100 IU/kg vs rFVIIa 90 - 120 mcg/kg x 2 doses - Bleeding stop
Study ID Hours (number of
participants)
aPCC (%) rFVIIa (%) 90% CI of the difference
(%)
P value
Astermark 2007 2 (47) 53.2 38.3 0.06 to 29.72 0.495
6 (46) 76.1 65.2 -2.73 to 24.47 0.309
12 (45) 77.8 75.6 -11.92 to 16.37 0.069
24 (42) 90.5 85.7 -4.75 to 14.28 0.038
36 (41) 95.1 87.8 -1.45 to 16.09 0.075
48 (41) 95.1 92.7 4.48 to 9.36 0.001
The table reports the number and % of participants who judged the treatment efficacious for any treatment and any time point. The
90% CIs of the difference test the hypothesis of equivalence between the treatments. When considering the difference at 2 hours, it
has to be taken into account that this time point is before the administration of the second rFVIIa bolus.
aPCC: activated prothrombin complex concentrates
CI: confidence interval
rFVIIa: recombinant factor VIIa
Table 3. aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses - Pain scale
Study ID Outcome rFVIIa 270 mcg/kg
(N = 24)
rFVIIa 90 mcg/kg x 3
(n = 22)
aPCC 75 IU/kg
(n = 22)
Young 2008 Positive treatment response
(%)
45.8 54.5 27.3
The response was globally evaluated 9 hours after treatment. The positive response were defined as at least 3 positive assessments at 1,
3, 6 and 9 hours. The positive assessment was defined on the base of a 3-level scale (more pain, no difference, less pain). There were
no statistically significant differences between treatments (P = 0.219).
aPCC: activated prothrombin complex concentrates
rFVIIa: recombinant factor VIIa
Table 4. aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses - Mobility scale
Study ID Outcome rFVIIa 270 mcg/kg
(N = 24)
rFVIIa 90 mcg/kg x 3
(n = 22)
aPCC 75 IU/kg
(n = 22)
Young 2008 Positive treatment response
(%)
25.0 45.5 22.7
19Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with
haemophilia and inhibitors (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The response was globally evaluated 9 hours after treatment. The positive response were defined as at least 3 positive assessments at 1,
3, 6 and 9 hours. The positive assessment was defined on the base of a 3-level scale (more mobility, no difference, less mobility).
There were no statistically significant differences between treatments (P = 0.903).
aPCC: activated prothrombin complex concentrates
rFVIIa: recombinant factor VIIa
Table 5. aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses - Rescue medication use
Study ID Outcome rFVIIa 270 mcg/kg
(n = 24)
rFVIIa 90 mcg/kg x 3
(n = 22)
aPCC 75 IU/kg
(n = 22)
Young 2008 Participants requiring res-
cue medication n (%)
2 (8.3) 2 (9.1) 8 (36.4)
Participants with an insufficient treatment response within 6 hours of the first treatment administration were evaluated in the clinic
or by phone to consider the use of rescue medication. Rescue medication was defined as additional haemostatic treatment within 9
hours post first administration of trial product. The difference between rFVIIa 270 mcg/kg vs aPCC was statistically significant (P =
0.032). The efficacy difference between the aPCC treatment group and the rFVIIa 90 x 3 mcg/kg did not reach statistical difference
(P = 0.069).
aPCC: activated prothrombin complex concentrates
rFVIIa: recombinant factor VIIa
WH A T ’ S N E W
Last assessed as up-to-date: 16 October 2015.
Date Event Description
16 October 2015 New citation required but conclusions have not
changed
While no new trials have been included in the up-
date, after receiving additional data from trial authors,
the two included (cross-over) trials were re-analyzed us-
ing the marginal probabilities method (Becker 1993;
Elbourne 2002).
16 October 2015 New search has been performed Literature searches were performed and the manuscript
was updated
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H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 2, 2004
Date Event Description
15 February 2011 Amended Contact details updated.
7 July 2010 New search has been performed The search of the Group’s Coagulopathies Trials Reg-
ister identified six references to five new trials; two tri-
als have been included (Astermark 2007; Young 2008)
and the remaining three trials have been excluded
(Kavakli 2006; Pruthi 2007; Santagostino 2006).
The review protocol was modified to include people
with both haemophilia A and haemophilia B. No dif-
ference exists in the treatment of individuals with in-
hibitors in each of the two conditions. We therefore
see no reason to limit the review to individuals with
haemophilia A, even if most of the people with in-
hibitors are haemophilia A patients (inhibitor occur-
rence in haemophilia B is much more rare)
7 July 2010 New citation required and conclusions have changed A new review team has taken on this review and up-
dated it including twonew trialswhere previously none
were included
14 November 2008 Amended Converted to new review format.
15 February 2006 New search has been performed The search of theGroup’s Coagulopathies Trials Regis-
ter identified one reference (Villar 2004), this has now
been listed under ’Excluded studies’
11 February 2005 New search has been performed The search of the Group’s Coagulopathies Trials Reg-
ister identified one trial, but this was not eligible for
inclusion in the review
24 February 2004 New citation required and conclusions have changed Substantive amendment
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The review protocol was modified to include people with haemophilia A and haemophilia B, since no difference exists in the treatment
of individuals with inhibitor in the two conditions. Even if most of the individuals with inhibitors are people with haemophilia A
(inhibitor occurrence in haemophilia B is much more rare), there is no reason to limit the review to haemophilia A.
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